



**FOR IMMEDIATE RELEASE
NEWS RELEASE**

TSX Venture: AMF

**ONTARIO GENOMICS INSTITUTE COMPLETES SECOND INVESTMENT IN
AMORFIX TO ACCELERATE DEVELOPMENT OF A BLOOD TEST FOR
ALZHEIMER'S DISEASE**

TORONTO, ON, September 12, 2006 – Amorfix Life Sciences Inc. announced the issue of 47,619 common shares and 23,810 warrants to Genomics Ontario Inc, the investment arm of the Ontario Genomics Institute (OGI), for gross proceeds of \$50,000. This is the second investment by OGI in support of Amorfix's development of a blood diagnostic test for Alzheimer's disease. Each warrant entitles the holder to purchase one common share of Amorfix at an exercise price of \$1.05 for a term of two years. The common shares and warrants are subject to a four month hold period.

Pursuant to the subscription agreement, Amorfix will continue its development of a blood test for Alzheimer's disease, EP-AD™, based upon Amorfix's patent-pending EP technology. OGI will continue to assist Amorfix in accelerating its program for diagnosis of neurodegenerative diseases drawing on OGI's portfolio of state-of-the-art genomics and proteomics facilities, research and pre-commercial development in Ontario.

About OGI

The Ontario Genomics Institute is a private, not-for-profit corporation focused on building a globally-competitive life sciences industry in Ontario. Through its relationship with Genome Canada and the newly created Ontario Ministry of Research and Innovation (MRI) as well as other private and public sector partners, OGI helps Ontario-based scientists secure funding for genomics-driven research and commercialization.

For further information, visit www.OntarioGenomics.ca or contact:

Dr. Christian Burks, President & CEO
Ontario Genomics Institute
416-673-6598
CBurks@OntarioGenomics.ca

About Amorfix

Amorfix is an emerging theranostics company focused on the diagnosis and treatment of neurodegenerative diseases, where aggregated misfolded proteins (AMPs) are prevalent. These include aggregated misfolded prion protein which makes up "prions," the infectious agents of the Transmissible

Spongiform Encephalopathies (TSE), such as Bovine Spongiform Encephalopathy (BSE or "mad cow disease") and the human form, variant Creutzfeldt-Jakob Disease (vCJD), as well as degenerative diseases such as Alzheimer's Disease (AD), Amyotrophic Lateral Sclerosis (ALS) and Parkinson's Disease (PD). Amorfix was formed to commercialize epitope protection (EP) technologies and related discoveries to become the world leader on AMP diseases. The company will use this new knowledge to develop diagnostic kits, therapeutics and prophylactics for AMP diseases.

For further information, visit the website at www.amorfix.com or contact:

Dr. George Adams, President and CEO
Amorfix Life Sciences Ltd.
416-557-4647
george.adams@amorfix.com

James Parsons, CFO
Amorfix Life Sciences Ltd.
416-482-3814
james.parsons@amorfix.com

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Actual future results may differ materially from those contemplated. The risks, uncertainties and other factors that could influence the actual results are described in documents filed with regulatory authorities.